Prognostic implication of intratumoral metabolic heterogeneity in invasive ductal carcinoma of the breast
暂无分享,去创建一个
S. Son | Do-Hoon Kim | C. Hong | Choon-Young Kim | S. Jeong | Sang-Woo Lee | Jaetae Lee | B. Ahn
[1] I. Fidler,et al. Biological diversity in metastatic neoplasms: origins and implications. , 1982, Science.
[2] G. Heppner. Tumor heterogeneity. , 1984, Cancer research.
[3] G. Heppner,et al. Mutagenic activity of tumor-associated macrophages in Salmonella typhimurium strains TA98 and TA 100. , 1984, Cancer research.
[4] G. Heppner,et al. Therapeutic implications of tumor heterogeneity. , 1989, Seminars in oncology.
[5] Heppner Gh,et al. Therapeutic implications of tumor heterogeneity. , 1989 .
[6] T Ido,et al. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. , 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[7] T. Ido,et al. Microautoradiographic study for the differentiation of intratumoral macrophages, granulation tissues and cancer cells by the dynamics of fluorine-18-fluorodeoxyglucose uptake. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[8] R. Wahl,et al. Intratumoral distribution of tritiated fluorodeoxyglucose in breast carcinoma: I. Are inflammatory cells important? , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[9] H. Yagata,et al. Predicting the prognoses of breast carcinoma patients with positron emission tomography using 2‐deoxy‐2‐fluoro[18F]‐D‐glucose , 1998, Cancer.
[10] R. Gillies,et al. Causes and effects of heterogeneous perfusion in tumors. , 1999, Neoplasia.
[11] S. Ramón y. Cajal,et al. Tumor heterogeneity: morphological, molecular and clinical implications. , 2000, Histology and histopathology.
[12] F. Chapon,et al. Non-invasive grading of oligodendrogliomas: correlations between in vivo metabolic pattern and histopathology , 2000, European Journal of Nuclear Medicine.
[13] Leila Mohammadi,et al. BMC Cancer , 2001 .
[14] P. Grigsby,et al. Measurement of tumor volume by PET to evaluate prognosis in patients with advanced cervical cancer treated by radiation therapy. , 2002, International journal of radiation oncology, biology, physics.
[15] C. Compton,et al. AJCC Cancer Staging Manual , 2002, Springer New York.
[16] G. Semenza,et al. HIF-1 and tumor progression: pathophysiology and therapeutics. , 2002, Trends in molecular medicine.
[17] E. Berg,et al. World Health Organization Classification of Tumours , 2002 .
[18] T. Taguchi,et al. Preoperative evaluation of prognosis in breast cancer patients by [18F]2-Deoxy-2-fluoro-D-glucose-positron emission tomography , 2004, Journal of Cancer Research and Clinical Oncology.
[19] Peter Devilee,et al. Pathology and Genetics of Tumours of the Breast and Female Genital Organs , 2003 .
[20] L. Murphy,et al. Intermittent Hypoxia Induces Proteasome-Dependent Down-Regulation of Estrogen Receptor α in Human Breast Carcinoma , 2004, Clinical Cancer Research.
[21] G. Nicolson. Generation of phenotypic diversity and progression in metastatic tumor cells , 2004, Cancer and Metastasis Reviews.
[22] G. Heppner,et al. Tumor heterogeneity: biological implications and therapeutic consequences , 2004, Cancer and Metastasis Reviews.
[23] Nagara Tamaki,et al. Biologic correlates of intratumoral heterogeneity in 18F-FDG distribution with regional expression of glucose transporters and hexokinase-II in experimental tumor. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[24] R. Walker,et al. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Breast and Female Genital Organs , 2005 .
[25] Manuela Milani,et al. Hypoxia-inducible factor-1alpha expression predicts a poor response to primary chemoendocrine therapy and disease-free survival in primary human breast cancer. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.
[26] Manuela Milani,et al. Hypoxia-Inducible Factor-1α Expression Predicts a Poor Response to Primary Chemoendocrine Therapy and Disease-Free Survival in Primary Human Breast Cancer , 2006, Clinical Cancer Research.
[27] Cai Grau,et al. Dose painting: art or science? , 2006, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[28] J. Kaanders,et al. Mini Symposium: Pet—the Future from Anatomical to Biological Target Volumes: the Role of Pet in Radiation Treatment Planning , 2022 .
[29] Carissa A. Sanchez,et al. Genetic clonal diversity predicts progression to esophageal adenocarcinoma , 2006, Nature Genetics.
[30] Anthony Rhodes,et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. , 2006, Archives of pathology & laboratory medicine.
[31] I. Buvat,et al. Partial-Volume Effect in PET Tumor Imaging* , 2007, Journal of Nuclear Medicine.
[32] Johan Wennerberg,et al. 2-Deoxy-2-[18F] fluoro-D-glucose uptake and correlation to intratumoral heterogeneity. , 2007, Anticancer research.
[33] J. Steinbach,et al. Effect of increase of radiation dose on local control relates to pre-treatment FDG uptake in FaDu tumours in nude mice. , 2007, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[34] Philippe Lambin,et al. Correlation of intra-tumour heterogeneity on 18F-FDG PET with pathologic features in non-small cell lung cancer: a feasibility study. , 2008, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[35] H. Tsuda,et al. Clinicopathological and prognostic relevance of uptake level using 18F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in primary breast cancer. , 2008, Japanese journal of clinical oncology.
[36] J. Dick,et al. Stem cell concepts renew cancer research. , 2008, Blood.
[37] F. O’Sullivan,et al. Spatial Heterogeneity in Sarcoma 18F-FDG Uptake as a Predictor of Patient Outcome , 2008, Journal of Nuclear Medicine.
[38] Mike Partridge,et al. Evaluation of the role of 18FDG-PET/CT in radiotherapy target definition in patients with head and neck cancer , 2008, Acta oncologica.
[39] P. Grigsby,et al. Intratumoral Metabolic Heterogeneity of Cervical Cancer , 2008, Clinical Cancer Research.
[40] S. Fox,et al. Phosphorylated ERalpha, HIF-1alpha, and MAPK signaling as predictors of primary endocrine treatment response and resistance in patients with breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[41] T. Hoey. Drug Resistance, Epigenetics, and Tumor Cell Heterogeneity , 2010, Science Translational Medicine.
[42] B. Manaster. Spatial Heterogeneity in Sarcoma 18F-FDG Uptake as a Predictor of Patient Outcome , 2010 .
[43] M. Hatt,et al. Intratumor Heterogeneity Characterized by Textural Features on Baseline 18F-FDG PET Images Predicts Response to Concomitant Radiochemotherapy in Esophageal Cancer , 2011, The Journal of Nuclear Medicine.
[44] M. Sim,et al. AJCC Cancer Staging Manual 7th edition criteria for colon cancer: do the complex modifications improve prognostic assessment? , 2013, Journal of the American College of Surgeons.
[45] Guangyu Liu,et al. 18F-Fluoromisonidazole PET/CT: A Potential Tool for Predicting Primary Endocrine Therapy Resistance in Breast Cancer , 2013, The Journal of Nuclear Medicine.
[46] He N. Xu,et al. Characterizing the metabolic heterogeneity in human breast cancer xenografts by 3D high resolution fluorescence imaging , 2013, SpringerPlus.